Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Slow-release melarsoprol microparticles.

Stéphane Gibaud1, Adela Gaia, Alain Astier

  • 1Laboratoire de Pharmacie Clinique, UPRES EA 3452, Faculté de Pharmacie, 5, rue Albert Lebrun, 54000 Nancy, France. stephanie.gibaud@pharma.uhp-nancy.fr

International Journal of Pharmaceutics
|August 15, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The scientific controversy is essential.

Annales pharmaceutiques francaises·2026
Same author

Transdermal delivery of lornoxicam <i>via</i> transethosomal gel as a novel strategy for management of rheumatoid arthritis.

Drug development and industrial pharmacy·2026
Same author

Can Napoleon's skin disease and treatment be identified from paleoproteomic analyses of his last bathtub (1821)?

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

Unravelling the Role of Uncommon Hydrogen Bonds in Cyclodextrin Ferrociphenol Supramolecular Complexes: A Computational Modelling and Experimental Study.

International journal of molecular sciences·2023
Same author

Extended physicochemical stability of cetuximab in opened vials and infusion bags when stored at 4°C and 25°C.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2023
Same author

3D-Printed, Liquid-Filled Capsules of Concentrated and Stabilized Polyphenol Epigallocatechin Gallate, Developed in a Clinical Trial.

Antioxidants (Basel, Switzerland)·2023
Same journal

Artificial intelligence and CRISPR-based approaches for targeted delivery of bacteriophages.

International journal of pharmaceutics·2026
Same journal

A "three-in-one" nose-to-brain delivery strategy: intranasal vancomycin spray achieves simultaneous clearance of pneumococcal colonization, bacteremia, and meningitis.

International journal of pharmaceutics·2026
Same journal

10-Hydroxy-2-decenoic acid /matrine deep eutectic solvent encapsulated in hyalurosomes for enhanced transdermal delivery and antioxidant efficacy.

International journal of pharmaceutics·2026
Same journal

Dual-trigger hyaluronic acid nanoprodrug incorporating a 2-nitrobenzenesulfonyl linker for CD44-targeted and glutathione-responsive drug delivery.

International journal of pharmaceutics·2026
Same journal

Polymeric mixed micellar nanogel enhances dermal delivery and therapeutic efficacy of tofacitinib citrate.

International journal of pharmaceutics·2026
Same journal

Localized gold nanoparticles-mediated photothermal therapy for head and neck cancer: in vivo proof-of-concept.

International journal of pharmaceutics·2026
See all related articles

The suspension-in-oil-in-water (S/O/W) method effectively prepared melarsoprol microparticles for human trypanosomiasis treatment. This S/O/W process yielded higher drug incorporation and sustained release compared to the water-in-oil-in-water (W(CD)/O/W) method.

Area of Science:

  • Pharmaceutical Technology
  • Drug Delivery Systems
  • Medicinal Chemistry

Background:

  • Melarsoprol is a crucial drug for treating human African trypanosomiasis.
  • Melarsoprol exhibits poor solubility in both aqueous and organic solvents, complicating formulation.
  • Effective microparticle formulation is needed to improve melarsoprol delivery and efficacy.

Purpose of the Study:

  • To compare two distinct methods for preparing Poly(epsilon -caprolactone) microparticles loaded with melarsoprol.
  • To evaluate the drug incorporation efficiency and release kinetics of the formulated melarsoprol microparticles.
  • To identify an optimal method for developing sustained-release melarsoprol formulations.

Main Methods:

  • Formulation of melarsoprol microparticles using modified oil-in-water (O/W) and water-in-oil-in-water (W/O/W) solvent evaporation techniques.

Related Experiment Videos

  • Comparison of a suspension-in-oil-in-water (S/O/W) method with a water-in-oil-in-water method involving methyl beta-cyclodextrin complexation (W(CD)/O/W).
  • Assessment of melarsoprol incorporation and in vitro drug release in a phosphate buffer/propylene glycol mixture.

    • Main Results:

    • The W(CD)/O/W method resulted in poor melarsoprol incorporation (2.89 +/- 0.20 microg mg(-1)).
    • The S/O/W method achieved significantly higher melarsoprol incorporation (161 +/- 5 microg mg(-1)).
    • S/O/W microparticles demonstrated sustained drug release, with approximately 50% released in 2 hours and 80% after 7 hours.

    Conclusions:

    • The S/O/W solvent evaporation method is highly effective for preparing melarsoprol microparticles.
    • This S/O/W method facilitates the development of sustained-release formulations for melarsoprol.
    • The findings suggest a promising approach for improving melarsoprol delivery in trypanosomiasis treatment.